脂蛋白(a)与钙化性主动脉瓣疾病的研究进展

Research progress of lipoprotein(a)and calcified aortic valve disease

钙化性主动脉瓣疾病是常见的心血管疾病,随着人口老龄化的日益加剧其逐渐成为主要的医疗负担。瓣膜置换术是该病的主要治疗方法,但高龄群体手术风险较大,并发症发生率高。且目前仍缺少预防或减缓疾病进展的有效药物。研究发现,脂蛋白(a)在瓣膜钙化的病理过程中起关键作用,脂蛋白(a)水平升高是钙化性主动脉瓣疾病的重要危险因素,显著增加主动脉瓣狭窄的患病风险。本文综述了脂蛋白(a)在钙化性主动脉瓣疾病的病理机制中的作用及其与治疗方面的相关性。

Calcified aortic valve disease is a common cardiovascular disease.With the aging of the population,it becomes a major medical burden.Valve replacement is the main treatment of the disease,but the elderly group has a high risk of operation and a high incidence of complications.There are still no drugs to prevent or slow the progression of the disease.It has been found that lipoprotein(a)plays a key role in the pathophysiology of valvular calcification.The increase of lipoprotein(a)level is an important risk factor for calcified aortic valve disease and can increase the risk of aortic stenosis.This article reviews the pathological mechanism of lipoprotein(a)involved in calcified aortic valve disease,and the therapy of calcified aortic valve disease.